Join us on Corporate Workshop Day, and on the Innovation Spotlight Stage!

We’re hosting 3 talks on Corporate Workshop Day — Wednesday, October 31 – from 2:00 to 4:00 pm in room 221 A and B

TALK 1

GeneReader: A complete end-to-end NGS solution for clinical cancer research

Speakers: Dr. Sergio Marchini, PhD, Head, Translational Genomic Unit, Department of Oncology, Mario Negri Institute for Pharmacological Research, Milano, Italy
Dr. Suman Verma, VP of Genomics Services, ResearchDx, California, USA
Prof. Dr. Peter J. Wild, Director of the Senckenberg Institute for Pathology, University Hospital Frankfurt, Germany

Date: Oct 31, 2018   Time: 2:00 – 2.50 pm CDT   Room: 221 A and B

Recent years have seen revolutionary advances in our collective understanding of the genetic basis of cancer. Many of these developments, especially in the field of prognostic and diagnostic biomarker discovery have been made possible by technologies like next generation sequencing. With these insights driving development of groundbreaking targeted therapies, there has never been a more exciting or important time to be a researcher in translational oncology research. Each of our 3 speakers at AMP is at the forefront in this field and will be sharing their latest discoveries and experiences with NGS in the oncology space.

Dr. Sergio Marchini will present data on BRCA 1/2 generated on a sample to insight NGS solution, Dr. Suman Verma will speak about verification of the GeneReader NGS System workflow with a comprehensive lung cancer panel, while Prof. Peter Wild will present data from the German Genomic Medicine Network, generated using a customized QIAact targeted panel.

TALK 2

Identification of inherited genetic risk factors of pancreatic cancer using a targeted sequencing approach in a large cohort

Speaker: Fergus Couch, PhD, Mayo Clinic, USA
Date: Oct 31, 2018    Time: 3:00 – 3.50 pm CDT    Place: Room: 221 A and B

Pancreatic cancer has one of the worst survival outcomes for any type of cancer. Given the high fatality rates, identifying individuals at risk by testing for inherited susceptibility is crucial for improving outcomes. Join us in this workshop to hear Dr. Fergus Couch from the Mayo Clinic discussing his lab’s study where 21 cancer predisposition genes were sequenced using a QIAseq targeted DNA panel to determine which ones were associated with an increased risk for pancreatic cancer. The study consisted of 3,030 cases and 123,136 controls and discovered genes independently associated with disease. Dr. Couch will present the results of this study and outline methodologies to overcome challenges associated with targeted sequencing in large studies.

TALK 3

Improving syndromic respiratory testing with QIAGEN’s DiagCORE system

Speaker: Steve Young, PhD, TriCore Reference Laboratories, Albuquerque
Date: Oct 31, 2018   Time: 4:00 – 4.50 pm CDT   Room: 221 A and B

Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens, and may share similar clinical presentations. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens. Join Dr. Steve Young at our corporate workshop where he will present a new technology for multiplexed respiratory testing in acutely ill patients. He will be sharing data demonstrating the capabilities of the DiagCORE system for syndromic respiratory testing. Dr. Young will also be sharing his impressions on the ease of doing comprehensive syndromic testing using the QIAGEN solution.

The QIAstat-Dx is coming soon.

We’re hosting two talks on the Innovation Stage on the show floor on Thursday, November 1, and Friday, November 2, from 12:00 to 12:30 pm

Better Knowledge, Better Care: Precision medicine for any cancer, any assay, on your platform

Speaker: Dan Richards, PhD, QIAGEN

Date: Nov 1, 2018   Time: 12:00 – 12.30 pm CDT

Whether cost, complexity or capacity, today’s clinical labs face significant roadblocks in delivering precision medicine insights to pathologist communities and their patients. QIAGEN helps your team focus on the opportunities, not the obstacles, with an end-to-end clinical testing solution. During this talk, Dan Richards, Vice President of Biomedical Informatics at QIAGEN and co-founder of Ingenuity Systems, will present a lung cancer case study to show how QIAGEN Clinical Insight (QCI®), our flexible clinical decision support suite, automates, accelerates and advances the interpretation and reporting of genetic variants. Compatible with any NGS platform, running any assay, targeting somatic, hereditary, hematological or childhood cancers, QCI Interpret classifies variants according to professional guidelines using multiple lines and levels of evidence that you can easily review. When coupled with QCI Analyze Universal, our new push-button software for the secondary analysis of NGS data, QCI Interpret makes it easier—and in many cases feasible—to deploy an end-to-end workflow to extract clinically actionable information from cancer tests data.

Improving syndromic respiratory testing with QIAGEN’s DiagCORE system

Speaker: Jan Gorm Lisby, MD, PhD, Section Chief, Department of Clinical Microbiology, Hvidovre Hospital, Copenhagen, Denmark

Date: Nov 2, 2018   Time: 12:00 – 12.30 pm CDT

Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens, and may share similar clinical presentations. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens. Join Dr. Gorm Lisby at our Innovation Spotlight Stage where he will present a new technology for multiplexed respiratory testing in acutely ill patients. He will be sharing data demonstrating the capabilities of the DiagCORE system for syndromic respiratory testing. Dr. Lisby will also be sharing his impressions on the ease of doing comprehensive syndromic testing using the QIAGEN solution.

The QIAstat-Dx is coming soon.

Social Sharing